Every material Form 8-K Celcuity Inc. has filed with the SEC since September 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Celcuity reported a third-quarter 2026 net loss of $73.3 million, or $1.33 per share, up from $43.8 million, or $0.92 per share, a year earlier. The company recognized no product revenue in the quarter because REVTORPYK shipments began on September 30, 2026, and revenue is recognized only on delivery, so the larger loss reflects launch spending.
Net loss was $73.3 million, or $1.33 per share, versus $43.8 million, or $0.92 per share, in Q3 2025.
No REVTORPYK product revenue was recognized in the quarter; shipments began September 30, 2026.
SG&A expenses rose to $39.8 million from $12.4 million, with $25.3 million of the increase tied to commercialization.
Cash, cash equivalents and short-term investments were $642.7 million at September 30, 2026, which the company expects will fund operations through 2029.
Celcuity's Board increased its size from eight to nine members on October 1, 2026, and appointed David W. Gryska, a former Incyte and Celgene CFO, as a director effective immediately. He also joined the Audit and Compensation Committees, a change in board composition rather than a financial or operational development.
Board expanded from eight to nine members; Gryska fills the new seat effective immediately, with a term through the 2027 Annual Meeting
Gryska is determined independent under Nasdaq and SEC rules and joins the Audit and Compensation Committees
Compensation includes a $70,000 annual cash retainer and a $100,000 annual equity award, plus a pro-rated grant of 893 restricted stock units
Celcuity announced on September 30, 2026 that REVTORPYK (gedatolisib) is now commercially available in the United States, following FDA approval on July 14, 2026 for certain HR+/HER2- advanced breast cancer patients without a PIK3CA mutation. The filing marks the start of commercial sales for the company's first FDA-approved product, though it does not disclose any sales, revenue or financial figures.
FDA approved REVTORPYK on July 14, 2026, in combination with palbociclib and fulvestrant, and with fulvestrant alone.
Eligible patients are those with HR+/HER2- advanced breast cancer without a PIK3CA mutation who progressed after at least one line of endocrine therapy in the metastatic setting.
Celcuity launched the REVTORPYK Support Services program to help with insurance coverage and financial assistance.
A supplemental New Drug Application for the PIK3CA mutated population was submitted to the FDA in August 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Celcuity Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →